Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 25,000 | |||
5 mg | 在庫あり | ¥ 55,000 | |||
10 mg | 在庫あり | ¥ 81,000 | |||
25 mg | 在庫あり | ¥ 136,500 | |||
50 mg | 在庫あり | ¥ 195,000 | |||
100 mg | 在庫あり | ¥ 268,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 80,000 |
説明 | Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study. |
ターゲット&IC50 | CGRP (human):0.023 nM (Ki) |
別名 | Vazegepant HCl |
分子量 | 675.3 |
分子式 | C36H47ClN8O3 |
CAS No. | 1414976-20-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (44.43 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vazegepant hydrochloride 1414976-20-7 GPCR/G Protein Neuroscience CGRP Receptor gepant Zavegepant Calcitonin gene-related peptide receptor receptor COVID-19 BHV3500 BHV-3500 BHV 3500 Vazegepant inhibit inflammation migraine intranasal Vazegepant HCl Inhibitor CGRP soluble Vazegepant Hydrochloride inhibitor